SOURCE: Market Pulse

May 16, 2005 08:30 ET

Market Pulse Breaking News Alert for Monday, May 16, 2005: BIPH - Biophan Signs Letter of Intent for the Exclusive License to Breakthrough Technology for MRI Visualization Inside Implanted

Vascular Stents!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Market Pulse.

ATLANTA, GA -- (MARKET WIRE) -- May 16, 2005 -- Market Pulse News Alert for this AM, Stocks to Watch are: Biophan Technologies, Inc. (OTC BB: BIPH), Dell Inc. (NASDAQ: DELL), Oracle Corp. (NASDAQ: ORCL), and Intel Corp. (NASDAQ: INTC).

Investors need to be watching Biophan Technologies, Inc. (OTC BB: BIPH) this AM! Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. Biophan's technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Biophan has joint development arrangements with Boston Scientific and NASA's Ames Center for Nanotechnology. BIPH has had several excellent news announcements lately and one again after Friday's bell regarding signing a letter of intent for the exclusive license to its breakthrough technology for MRI visualization inside implanted vascular stents! This could be great news for investors!

Biophan Technologies, Inc. (OTC BB: BIPH) has executed a letter of intent with leading German biomedical researchers, Dr. Arno Bucker and Dr. Alexander Ruebben, for an exclusive license to their breakthrough cardiovascular stent technology enabling accurate Magnetic Resonance Imaging (MRI) angiography of the interior of vascular stents. The technology, developed by Dr. Bucker and Dr. Ruebben through their research at the University of Aachen in Germany, is designed to enable MRI visualizations to diagnose the health of implanted stents and assess the occurrence of restenosis, or unhealthy re-narrowing of stented arteries.

Dr. Bucker and Dr. Ruebben have published details of their research in various scientific journals, most recently in the medical journal "Circulation" (http://circ.ahajournals.org/cgi/content/full/105/15/1772). They have tested several prototypes of their Aachen resonance renal MRI stents and have reported on the technology's ability to enable artifact-free MRI Angiography and coronary vessel wall imaging within implanted stents. They have conducted their studies in both in vitro and in swine models. Biophan has signed a letter of intent to serve as exclusive worldwide licensor of the technology.

Together with the existing technology already held by Biophan, which was obtained through their recent acquisition of aMRIs GmbH, the letter of intent with Dr. Bucker and Dr. Ruebben will give Biophan licensing ownership to two of the most promising methods to create artifact-free images of stents and implants with MRI systems. "The synergies between our technologies could lead to really exciting new developments," commented Michael Friebe, PhD, CEO of Biophan Europe. "We are especially excited to add two renowned experts to our team, who are among the leading interventional MRI researchers in the world. We are confident that their expertise and experience will further improve Biophan's research and development programs."

Dr. Bucker, a clinical professor of radiology at the University of Aachen, is one of the leading experts in interventional MRI. The University of Aachen is a renowned clinical research institution and one of the leading radiology research centers in the world and is led by Prof. Rolf Gunther. Dr. Bucker and Dr. Ruebben will continue to work on further improving the stent as part of a consulting agreement with Biophan Europe.

"This letter of intent adds an important component of technology and expertise to the overall Biophan portfolio," said Michael Weiner, CEO of Biophan. "Drs. Bucker and Reubben are world-renowned scientist/physicians conducting cutting-edge research in MRI diagnostics and innovative stent and medical device designs. The technology that will be licensed to Biophan, and will be available for sub-licensing by us to third parties, adds another viable means to creating MRI visible stents that can allow exquisite detail of restenosis and blockages, without the need for an interventional procedure, and eliminating the need to expose the patient to toxic dyes and ionizing radiation. The Aachen solution builds on the resonant circuit technologies we are already working on, and adds an exciting alloy metal for alternative stent designs. With the achievement of this working relationship, organized by Biophan Europe, we now offer a complete line of solutions for making MRI-visible stents, and will be in possession of all the known viable solutions that we are aware of. The only other approaches we know of for making an MRI visible stent require cutting the struts of the stent and gluing them back together, which is a solution that has not been well received due to the damage to stent structural integrity that may occur. Biophan is looking forward to working with its strategic partners to bring MRI visible stents to the marketplace."

Due to its excellent image quality, diagnostic accuracy and overall safety, MRI-based angiography is increasingly replacing diagnostic X-ray angiography for vascular imaging throughout the body. MRI angiography has not been able to visualize the interior of metallic stents, however, because current generations of stents -- whether made of stainless steel or nitinol -- do not allow visualization of the stent lumen and/or create image artifacts. Consequently, MRI has not been effective for diagnosing restenosis, one of the most serious medical problems for patients who have received implanted vascular stents. Biophan is a leading force in the development of technology to make medical devices imageable and safe in the environments of MRI systems.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 114 U.S. patents, licenses, or applications. This total includes 36 issued U.S. patents, 6 recently allowed applications that will issue as patents in the near future, and 72 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Stocks acting well as of late include: Dell Inc. (NASDAQ: DELL), Oracle Corp. (NASDAQ: ORCL), and Intel Corp. (NASDAQ: INTC).

Information contained herein is the opinion of Market-Pulse.com ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated one hundred fifty thousand dollars from Biophan Technologies, Inc. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives free trading shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services. Market Pulse News Alert is a division of MP.

Contact Information